Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02194049 | Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer | completed | Phase 1 | 3 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01987362 | A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies | completed | Phase 1 | 52 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2018 |
| NCT03389815 | A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 48 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 4, 2018 | clinicaltrials |
| NCT00921869 | A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Eisai Co., Ltd.INDUSTRY | 1 | Dec 26, 2017 | clinicaltrials |
| NCT02164097 | ODSH + ICE Chemotherapy in Pediatric Solid Tumors | terminated | Phase 1 | 4 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00098514 | Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 53 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03313219 | Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China | unknown | Phase 1 | 20 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 12, 2017 | clinicaltrials |
| NCT03266159 | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 8, 2017 | clinicaltrials |
| NCT02940132 | A Study of SC10914 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 72 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00899522 | Tissue Sample Collection From Patients With Fanconi Anemia | completed | — | 8 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 4, 2017 | clinicaltrials |
| NCT00622674 | Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 37 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01072266 | A Dose-escalation Study in Subjects With Advanced Malignancies | completed | Phase 1 | 45 | Incyte CorporationINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00718380 | A Phase 1 Study of ABT-869 in Subjects With Solid Tumors | completed | Phase 1 | 18 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00733187 | Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869 | completed | Phase 1 | 34 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00887757 | Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors | completed | Phase 1 | 46 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00891605 | Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors | completed | Phase 1 | 19 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT00982566 | Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer | completed | Phase 1 | 37 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01121133 | A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax | completed | Phase 1 | 12 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01199224 | To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 27 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01255657 | A Study of ABT-806 in Subjects With Advanced Solid Tumor Types | completed | Phase 1 | 49 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 21, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT01413893 | An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01472016 | Study of ABT-700 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 74 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01009073 | A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects | completed | Phase 1 | 51 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01617928 | A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors | completed | Phase 1 | 12 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02009631 | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | completed | Phase 1 | 45 | AbbVieINDUSTRY | 3 | Nov 20, 2017 | clinicaltrials |
| NCT02593708 | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | terminated | Phase 1 | 6 | Michelle MeliskoOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01767454 | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | completed | Phase 1 | 38 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00483860 | A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function | completed | Phase 1 | 59 | GlaxoSmithKlineINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT00687622 | Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | completed | Phase 1 | 206 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00732420 | Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | completed | Phase 1 | 68 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT01324258 | Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | completed | Phase 1 | 19 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00389584 | Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors | completed | Phase 1 / Phase 2 | 30 | University of California, DavisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01331941 | A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function | completed | Phase 1 | 35 | AmgenINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00182780 | American Ginseng in Treating Patients With Cancer-Related Fatigue | completed | N/A | 290 | Alliance for Clinical Trials in OncologyOTHER | 0 | Oct 31, 2017 | clinicaltrials |
| NCT03326479 | POA Retrospective Repository | unknown | — | 10,000 | Caris Science, Inc.INDUSTRY | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02093325 | A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia | unknown | Phase 3 | 83 | Chang Gung Memorial HospitalOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT00871910 | Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | completed | Phase 1 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 23, 2017 | clinicaltrials |
| NCT01473095 | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | completed | Phase 1 | 120 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT01159522 | A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy | completed | Phase 1 | 33 | SynCore Biotechnology Co., Ltd.INDUSTRY | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01749384 | Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00499135 | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2017 | clinicaltrials |
| NCT01252095 | Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours | terminated | Phase 1 | 4 | Zucero Pty LtdINDUSTRY | 1 | Oct 9, 2017 | clinicaltrials |
| NCT02042781 | Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | completed | Phase 1 | 23 | Zucero Pty LtdINDUSTRY | 1 | Oct 9, 2017 | clinicaltrials |
| NCT01581541 | PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment | terminated | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Oct 4, 2017 | clinicaltrials |
| NCT02100007 | ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | MEI Pharma, Inc.INDUSTRY | 2 | Oct 2, 2017 | clinicaltrials |
| NCT01227954 | Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases | completed | Phase 2 | 113 | Radiation Therapy Oncology GroupNETWORK | 2 | Sep 27, 2017 | clinicaltrials |
| NCT00136578 | Ispinesib In Combination With Carboplatin In Patients With Solid Tumors | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 2 | Sep 25, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jan 9, 2018source: clinicaltrials